|Toxiciy Grade:||5||City/State/Province:||Queens, New York|
|Treatments:||Chemotherapy, Surgery||Hospital:||Queens Hospital Center|
Patients: This trial involved patients with one to three potentially resectable metastases of colorectal carcinoma to the liver. There were a total of 75 “assessable” patients in this trial divided into two groups. The “Control” group contained 45 patients and the “Chemotherapy” group contained 30 patients.
Treatment: Treatment in the Control group involved surgery only. Treatment in the Chemotherapy group involved surgery plus postoperative hepatic arterial floxuridine (FUDR)combined with intravenous continuous-infusion fluorouracil (5-FU, adrucil).
Toxicity: There were two postoperative deaths from operative complications – one in each group. The toxicities of chemotherapy (Chemotherapy group) included increases in liver enzymes (grade 3), biliary sclerosis, leukopenuia (grade 2), thrombocytopenia (grade 1), diarrhea (grade 1), vomiting (grade 2), and nausea (grade 3).
Results: The median survival of the chemotherapy group was 63.7 months.
Correspondence: M. Margaret Kemeny, MD